Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5α-reductase inhibitor

Prostate

Volumn 28, Issue 3 SUPPL. 6, 1996, Pages 62-66

  Sutkowski, Debra M ^a   Audia, James E ^a   Goode, Robin L ^a   Hsiao, Kenneth C ^a   Leibovitch, Ilan Y ^b   McNulty, Ann M ^a   Neubauer, Blake Lee ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

dihydrotestosterone; LY300502

Indexed keywords

8 CHLORO 1,2,3,4,4A,5,6,10B OCTAHYDRO 4 METHYLBENZO[F]QUINOLIN 3(2H) ONE; 8 CHLORO 1,4,4A,5,6,10B HEXAHYDRO 4 METHYLBENZO[F]QUINOLIN 3(2H) ONE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; ANDROSTANOLONE; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR; OXIDOREDUCTASE; QUINOLONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG RESPONSE; DRUG STRUCTURE; MITOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TESTOSTERONE METABOLISM; ADENOCARCINOMA; ARTICLE; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SECRETION;

ADENOCARCINOMA; CELL DIVISION; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; HUMANS; MALE; OXIDOREDUCTASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINOLONES; TUMOR CELLS, CULTURED;

EID: 0029684527     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(1996)6+<62::aid-pros12>3.0.co;2-p     Document Type: Conference Paper

References (19)

1. Bruchovsky N, Wilson JD: The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012-2021, 1968.
2. Russell DW, Wilson JD: Steroid 5α-reductase: Two genes/two enzymes. Annu Rev Biochem 63:25-61, 1994.
3. Audia JE, Lawhorn DE, Deeter JB: Synthesis of the individual enantiomers of the benzoquinolinone human type 1 steroid 5α-reductase inhibitors, LY191704 and LY266111. Tetrahedron Lett 34:7001-7004, 1993.
4. Jones CD, Audia JE, Lawhorn DE, McQuaid LA, Neubauer BL, Pike AJ, Pennington P, Stamm NB, Toomey RE, Hirsch KS: Nonsteroid inhibitors of type I steroid 5-α-reductase. J Med Chem 36:421-423, 1993.
5. Hirsch KS, Jones CD, Audia JE, Andersson, S, McQuaid L, Neubauer BL, Pike AJ, Pennington PA, Stamm NB, Toomey RE, Russell DW: LY191704: A selective, non-steroidal inhibitor of human steroid 5α-reductase type I. Proc Natl Acad Sci USA 90:5277-5281, 1993.
6. Neubauer BL, Farid NA, Gray HR, Hanke CW, Hirsch KS, Hsiao KC, Lawhorn DE, McQuaid L, Toomey RE, Valia K, Audia JE: LY191704: Human type I-selective steroid 5α-reductase inhibitor [trans-8-chloro-1,4,4a,5, 6,10b-hexahydro-4-methylbenzo [f] quinolin-3(2H)-one]. Drugs Future 20:144-197, 1995.
7. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu MT, Mirand EA, Murphy GP: LN-CaP model of human prostatic carcinoma. Cancer Res 43:1908-1918, 1983.
8. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM: Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LN-CaP, by dihydrotestosterone. Endocrinology 136:796-803, 1995.
9. TM Version 2 User's Guide." Cary NC: SAS Institute, Inc., 1989, pp 273-276.
10. Harris G, Azzolina B, Baginsky W, Cimis G, Rasmusson GH, Tolman RL, Raetz CRH, Ellsworth K: Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp. Proc Natl Acad Sci USA 89:10787-10791, 1992.
11. Neubauer BL, Audia JE, Best KL, Goode RL, Hirsch KS, Jones CD, Lawhorn DE, McQuaid LA, Pennington P, Stamm NB, Toomey RE: LY191704 selectively inhibits type I steroid 5α-reductase in human scalp skin. Presentation to the Royal Society of Medicine International Symposium on Androgenic Alopecia and Hirsuties, London, UK, April 28, 1993.
12. Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T, McLoughlin MG: Kinetic parameters of 5α-reductase activity in stroma and epithelium of normal, hyperplastic and carcinomatous human prostates. J Clin Endocrinol Metab 67:806-816, 1988.
13. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, Mc-Connell JD, Russell DW: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 92:903-910, 1993.
14. Kaefer M, Audia JE, Bruchovsky N, Goode RL, Hsiao KC, Krushinski JH, Lee C, Leibowitz IY, Steidle CP, Sutkowski DM, Neubauer BL: Characterization of type I steroid 5α-reductase in DU145 human prostatic adenocarcinoma cells. J Steroid Biochem Mol Biol (in press).
15. Delos S, Iehle C, Martin PM, Raynaud JP: Inhibition of the "basic" 5α-reductase (type I) detected in DU145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 48:347-352, 1994.
16. Negri-Cesi P, Motta M, Mornati O: Androgen metabolism in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 51:89-96, 1994.
17. Stoner EJ: The clinical development of a 5 alpha-reductase inhibitor, finasteride. Steroid Biochem Mol Biol 37:375-378, 1990.
18. Gormley GJ: Chemoprevention strategies for prostate cancer: The role of 5 alpha-reductase inhibitors. J Cell Biochem [Suppl] 16:113-117, 1992.
19. Presti JC Jr, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D, Ng J, Gormley GJ: Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 148:1201-1204, 1992.